Mbx Biosciences, Inc. MBX
We take great care to ensure that the data presented and summarized in this overview for MBX Biosciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in MBX
Top Purchases
Top Sells
About MBX
Insider Transactions at MBX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 16
2024
|
Ali Behbahani |
BUY
Open market or private purchase
|
Indirect |
500,000
+12.15%
|
$8,000,000
$16.0 P/Share
|
|
Sep 16
2024
|
Ali Behbahani |
BUY
Conversion of derivative security
|
Indirect |
3,114,486
+45.09%
|
-
|
|
Sep 16
2024
|
Forest Baskett |
BUY
Open market or private purchase
|
Indirect |
500,000
+12.15%
|
$8,000,000
$16.0 P/Share
|
|
Sep 16
2024
|
Forest Baskett |
BUY
Conversion of derivative security
|
Indirect |
3,114,486
+45.09%
|
-
|
|
Sep 16
2024
|
Edward T Mathers |
BUY
Open market or private purchase
|
Indirect |
500,000
+12.15%
|
$8,000,000
$16.0 P/Share
|
|
Sep 16
2024
|
Edward T Mathers |
BUY
Conversion of derivative security
|
Indirect |
3,114,486
+45.09%
|
-
|
|
Sep 16
2024
|
Mohamad Makhzoumi |
BUY
Open market or private purchase
|
Indirect |
500,000
+12.15%
|
$8,000,000
$16.0 P/Share
|
|
Sep 16
2024
|
Mohamad Makhzoumi |
BUY
Conversion of derivative security
|
Indirect |
3,114,486
+45.09%
|
-
|
|
Sep 16
2024
|
Anthony A. Florence Jr. |
BUY
Open market or private purchase
|
Indirect |
500,000
+12.15%
|
$8,000,000
$16.0 P/Share
|
|
Sep 16
2024
|
Anthony A. Florence Jr. |
BUY
Conversion of derivative security
|
Indirect |
3,114,486
+45.09%
|
-
|
|
Sep 16
2024
|
Carmen Chang |
BUY
Open market or private purchase
|
Indirect |
500,000
+12.15%
|
$8,000,000
$16.0 P/Share
|
|
Sep 16
2024
|
Carmen Chang |
BUY
Conversion of derivative security
|
Indirect |
3,114,486
+45.09%
|
-
|
|
Sep 16
2024
|
Scott D Sandell |
BUY
Open market or private purchase
|
Indirect |
500,000
+12.15%
|
$8,000,000
$16.0 P/Share
|
|
Sep 16
2024
|
Scott D Sandell |
BUY
Conversion of derivative security
|
Indirect |
3,114,486
+45.09%
|
-
|
|
Sep 16
2024
|
Rick Yang |
BUY
Open market or private purchase
|
Indirect |
500,000
+12.15%
|
$8,000,000
$16.0 P/Share
|
|
Sep 16
2024
|
Rick Yang |
BUY
Conversion of derivative security
|
Indirect |
3,114,486
+45.09%
|
-
|
|
Sep 16
2024
|
Paul Edward Walker |
BUY
Open market or private purchase
|
Indirect |
500,000
+12.15%
|
$8,000,000
$16.0 P/Share
|
|
Sep 16
2024
|
Paul Edward Walker |
BUY
Conversion of derivative security
|
Indirect |
3,114,486
+45.09%
|
-
|
|
Sep 16
2024
|
James M Cornelius |
BUY
Conversion of derivative security
|
Direct |
102,082
+50.0%
|
-
|
|
Sep 16
2024
|
Frazier Life Sciences X, L.P. |
BUY
Open market or private purchase
|
Direct |
625,000
+12.07%
|
$10,000,000
$16.0 P/Share
|
Last 12 Months Summary
Buy / Acquisition
57.3M
Shares
From
33
Insiders
| Conversion of derivative security | 48.8M shares |
|---|---|
| Open market or private purchase | 8.5M shares |
Sell / Disposition
0
Shares
From
0
Insiders